Zions Bancorporation of Salt Lake City, Utah, would have a lower capital cushion against losses in a sharp downturn than the Fed requires, according to results of the central bank's annual "stress test." The firm's Tier 1 common ratio, which measures high-quality capital as a share of risk-weighted assets, would be 3.5%, below the Fed's 5% minimum.
Zions, which operates more than 480 branches in the western U.S., had net earnings of $294 million in 2013, up from $179 million in 2012.
The Fed is expected to announce next week whether it will reject the plans of Zions or any of the other large banks to issue dividends or buy back stock shares. Other banks' plans could be denied even if they meet minimum capital standards if the Fed determines that their supervision is lacking. A firm whose plan is rejected has 30 days to modify and resubmit it.
10 Best Up And Coming Stocks To Watch Right Now: Edp Energias de Portugal SA (EDPFY.PK)
EDP Energias de Portugal SA (EDP), incorporated in 1976, is a Portugal-based company engaged in the electric energy and gas sectors. The Company develops its activities in the business areas of generation, supply and distribution of electricity and supply and distribution of gas. The Company operates through six business units: Electricity Generation, Renewable Energies, Electricity Distribution, Electricity Supply, Gas and Brazil Operations. EDP is also present in electricity generation, supply and distribution in Brazil, Spain and the United States. In April 2008, the Company acquired EDP Renovaveis through Nuevas Energias de Occidente (NEO). In February 2008, Horizon Wind Energy, LLC, EDP�� 100%-owned subsidiary for United States wind operations, acquired from Hydra Energy, LLC, a portfolio of six early stage projects in an aggregate of 1,050 megawatts of wind capacity, located in the States of Illinois, Indiana and Ohio, the United States.
Electricity Generation
In Spain, EDP operates through HC Energia. Cogeneration consists of simultaneous production of power and steam using thermal technology, such as in the form of natural gas turbines. Cogenerators are usually attached to an industrial customer or services, to which they supply the electricity and steam they need. Energy generation includes a centralised energy management platform responsible for actively managing the price and volume risks for the EDP Company�� portfolio in the Iberian Peninsula.
Renewable Energies
The Company�� electricity from renewable energies is generated by its subsidiary NEO, and in the United States of America by its subsidiary Horizon Wind Energy. In July 2007, EDP acquired 100% interest in Horizon, a developer, owner and operator of wind power generation in the United States, from the Goldman Sachs Group, Inc. In September 2007, Horizon owned 941 gross megawatt of operating wind projects and has 615 megawatt of projects under construction, for expected operational ! capacity of 1.556 gross megawatts (1.324 net megawatts).
Electricity Distribution
EDP develops the regulated electricity distribution activity in mainland Portugal and in Spain in the Asturias region and to a lower extent in Madrid, Valencia and Alicante. Electricity distribution activity is a regulated activity that consists in bringing the electricity, through the distribution network, from the transport network substations to the final consumption points. Within the scope of this activity, EDP builds, operates and maintains the distribution network and other installments aimed at electricity distribution, granting service quality and direct and customized assistance.
EDP Distribuicao Energia, S.A. is EDP�� company operating in the regulated distribution and supply businesses in Portugal. EDP�� distribution activity is regulated by energy service regulator (ERSE), which defines the tariffs, parameters and prices for electricity and other services in Portugal, controlling and assuring the levels of quality and service demanded by the Direccao Geral de Geologia e Energia (DGGE). EDP Distribuicao is holder of an open-ended binding license for the business of distribution of medium- and high-voltage electricity in mainland Portugal. It is also the concessionaire for almost all the low-voltage distribution network, in accordance with concession contracts with the municipalities. HC Energia operates in the regulated electricity distribution and supply business, with its natural market being the region of Asturias. HC Energia�� network covers the Asturias, Valencia, Madrid and Alicante regions.
Electricity Supply
EDP's electricity supply offers the services, such as maintenance and assistance services, services aimed at electricity quality, specialized technical services and energy efficiency services. EDP operates in Portugal through EDP Comercial, while in Spain, its electricity supply service is obtained from HC Energia or Naturgas, ! which off! ers its customers an integrated portfolio of gas and electricity products.
Gas
EDP has a presence in the gas sector in the Iberian Peninsula, through Naturgas in Spain, and through EDP Gas in Portugal. Naturgas market is the Basque Country, and Asturias, and it operates in the Spanish gas sector by providing services, such as transport, distribution and supply of gas; supply of gas in the liberalized market, and sourcing and trading.
Brazil Operations
EDP is present in Brazil through Energias do Brasil, a 62.4%-owned subsidiary. Energias do Brasil operates in the electricity generation, distribution and supply businesses.
Advisors' Opinion:- [By David Hunkar]
Current Dividend Yield: 6.43%
Company: Edp Energias De Portugal SA (EDPFY.PK)
Sector: Telecom
Country: AustraliaCurrent Dividend Yield: 4.68%
Sector: Electric Utilities
Country: Portugal
Top 10 Quality Companies To Watch In Right Now: Diana Containerships Inc.(DCIX)
Diana Containerships Inc. owns and operates containerships in Greece. The company engages in the seaborne transportation of semi-finished and finished consumer and industrial products. As of February 23, 2012, its fleet consisted of 8 containerships with a carrying capacity of approximately 32,693 twenty-foot equivalent units. Diana Containerships Inc. was founded in 2010 and is based in Athens, Greece.
Advisors' Opinion:- [By Monica Gerson]
Diana Containerships (NASDAQ: DCIX) is projected to report its Q1 earnings at $0.01 per share on revenue of $13.22 million.
Intrawest Resorts Holdings (NYSE: SNOW) is expected to post its Q3 earnings at $2.69 per share on revenue of $294.89 million.
Top 10 Quality Companies To Watch In Right Now: Prana Biotechnology Ltd (PRAN)
Prana Biotechnology Limited engages in the research and development of therapeutic drugs for the treatment of neurological disorders in Australia. The company primarily focuses on the Alzheimer�s, Parkinson�s, and Huntington�s diseases, as well as various cancer, age-related macular degeneration and cataract, Motor Neuron, and Creutzfeldt-Jakob diseases. Its development stage product line comprises PBT2, a Phase IIb clinical trial product for the treatment of Alzheimer�s disease; and PBT2, a Phase IIa clinical trial product for the treatment of Huntington�s disease. The company was formerly known as Prana Corporation Ltd. and changed its name to Prana Biotechnology Limited in January 2000. Prana Biotechnology Limited was founded in 1997 and is based in Parkville, Australia.
Advisors' Opinion:- [By Bryan Murphy]
Considering Eli Lilly & Co. (NYSE:LLY) as well as a co-development project between Johnson & Johnson (NYSE:JNJ) and Pfizer Inc. (NYSE:PFE) both failed in semi-recent effort to develop a similar-functioning Alzheimer's drug, it would be easy to assume that particular route towards an Alzheimer's might be the wrong path to take. Sometimes though, a small tweak or a seemingly-minor nuance with the underlying problem can make all the difference. Enter Prana Biotechnology Limited (NASDAQ:PRAN). Though the company acknowledges its focal point on the development of an Alzheimer's therapy is the same broad premise that ultimately led LLY, PFE, and JNJ to failure, PRAN may have found the proverbial missing link.
- [By Roberto Pedone]
Another under-$10 biotechnology player that's starting to trend within range of triggering a major breakout trade is Prana Biotechnology (PRAN), which researches and develops therapeutic drugs for the treatment of neurological disorders in Australia. This stock has been crushed by the bears so far in 2014, with shares off huge by 69%.
If you look at the chart for Prana Biotechnology, you'll notice that this stock recently formed a double bottom chart pattern at $1.90 to $2 a share right above its 50-day moving average of $1.84 a share. Shares of PRAN have been consolidating and moving sideways above its 50-day for the last few weeks. This stock is now starting to spike higher today right above those near-term support levels, and it's quickly pushing within range of triggering a major breakout trade above some key overhead resistance levels.
Market players should now look for long-biased trades in PRAN if it manages to break out above some near-term overhead resistance levels at $2.22 to $2.35 a share and then above some past overhead resistance at $2.47 a share with high volume. Look for a sustained move or close above those levels with volume that hits near or above its three-month average action of 1.98 million shares. If that breakout triggers soon, then PRAN will set up to re-test or possibly take out its gap-down-day high from April at $3.24 a share. Any high-volume move above that level will then give PRAN a chance to re-fill some of its previous gap-down-day zone that started at $10.30 a share.
Traders can look to buy PRAN off weakness to anticipate that breakout and simply use a stop that sits just below its 50-day moving average of $1.84 a share. One can also buy PRAN off strength once it starts to move above those breakout levels with volume and then simply use a stop that sits a comfortable percentage from your entry point.
- [By James Brumley]
SGNT stock is also valued at a palatable trailing P/E of 19.8, and has logged six straight quarterly earnings beats, making it one of the best cheap stocks in the pharmaceutical industry.
Prana Biotechnology (PRAN)It’s a slippery slope when you start placing bets based on a company with no marketable product, and a lead candidate that’s only in Phase 2 trials. But, Prana Biotechnology (PRAN) may be one of those cheap stocks within the drugmaking world that’s worth the risk.
Top 10 Quality Companies To Watch In Right Now: FBR & Co (FBRC)
FBR & Co., formerly FBR Capital Markets Corporation, is a full-service investment banking, institutional brokerage and asset management company. In addition, it makes principal investments, including merchant banking investments. The Company�� subsidiaries are FBR Capital Markets & Co. (FBR & Co.), FBR Capital Markets International, Ltd. (FBRIL), Financial Services Authority (FSA), and FBR Fund Advisers, Inc. (FBR Fund Advisers). Its segments include capital markets, which include investment banking and institutional brokerage and research; asset management, and principal investing, which includes merchant banking. It provides capital raising services, including underwriting and placement of public and private equity and debt; financial advisory services, including merger and acquisition advisory, restructuring, liability management, recapitalization and strategic alternative analysis; asset management services through a family of mutual funds; institutional sales and trading services focused on equities, equity-linked securities, listed options, high-yield bonds, senior debt and bank loans; and research coverage.
Capital Markets
The Company�� capital markets business is conducted by its investment banking and institutional brokerage professionals through its United States and United Kingdom broker-dealer subsidiaries. These professionals provide investment banking services, including capital raising and financial advisory services, and institutional brokerage services, including sales, trading, and research services, to its institutional clients across its core industry sectors.
Asset Management
The Company�� investment adviser subsidiaries principally manage a family of mutual funds. At December 31, 2011, it managed client assets through its 10 mutual fund product lines that cover a range of sectors and asset classes. Through attention to relative valuation and security selection, it manages mutual funds strive both to participate in rising m! arkets and preserve capital in down markets. It focuses on expanding its asset management business.
The Company�� investing activity consists primarily of investments in merchant banking investments, investments in publicly traded companies, and investments in short-term liquid instruments. This strategy involves putting its capital to work alongside the capital of its institutional clients.
Advisors' Opinion:- [By DAILYFINANCE]
Brian Smale/Microsoft via Getty ImagesNewly named Microsoft CEO Satya Nadella. SAN FRANCISCO -- After compiling a list of more than 100 CEO candidates, Microsoft settled on Satya Nadella a homegrown leader who joined the software maker in the early 1990s. That's back when Google's founders were teenagers and Facebook CEO Mark Zuckerberg was in elementary school. Tuesday's hiring of Nadella as Microsoft's CEO after a five-month search is a safe move that's likely to be greeted with sighs of relief around the company's Redmond, Wash., headquarters, industry analysts say. But the methodical, almost predictable decision is likely to reinforce perceptions that Microsoft (MSFT) is a plodding company reluctant to take risks as it competes against younger rivals who relish going out on a limb. While Google (GOOG) founder and CEO Larry Page boasts about his company taking "moon shots" and Zuckerberg promises to "move fast and break things," Microsoft has fallen behind the technological curve after underestimating the importance of Internet search more than a decade ago and reacting too slowly to the rise of mobile devices during the past seven years. Meanwhile, the sales of personal computers running on Microsoft's Windows software are shrinking. Microsoft's malaise may have narrowed the field of up-and-coming visionaries interested in running a company founded in 1975. Just as Microsoft founder Bill Gates and Apple (AAPL) founder Steve Jobs would never have considered working at IBM (IBM) in the 1980s, today's entrepreneurial whiz kids scoff at Microsoft's overtures. "Going to work at Microsoft could make it look like you are going back to the dark ages," says Richard Metheny, a management coach for the executive search firm Witt/Kieffer in Chicago. "It's a well-entrenched business that has had trouble lately figuring out how to play in this new world." Despite its challenges, Microsoft remains a moneymaking machine that sits atop an $84 billion cash pile. Tha
- [By Zachary Tracer]
FBR & Co. (FBRC) is leading the sale, according to a regulatory filing today from Emeryville, California-based NMI. The company said it�� seeking to raise $25 million, a placeholder amount used to calculate registration fees, according to the document.
Top 10 Quality Companies To Watch In Right Now: TESARO Inc (TSRO)
TESARO, Inc. (TESARO), incorporated in March 2010, is a development-stage, oncology-focused biopharmaceutical company for cancer patients. The Company focuses on rolapitant and TSR-011 product. The Company�� marketed products and product candidates in development treat cancer through non-specific damage to cellular components or alter cell metabolism or internal repair mechanisms to the demise of cancer cells.
Rolapitant
Rolapitant is a potent and long-acting neurokinin-1, or NK-1, receptor antagonist is in Phase III clinical trials for the prevention of chemotherapy induced nausea and vomiting (CINV). It is in Phase III clinical trials. CINV, if not prevented by prophylaxis, has the potential to afflict up to 90% or more of cancer patients undergoing chemotherapy, depending upon the type of chemotherapy administered the dosing schedule of the chemotherapy, and the patients' age and gender, among other predisposing factors. Prolonged nausea and vomiting may result in unwanted weight loss, dehydration and malnutrition, as well as hospitalization. The Company has in-licensed the rights to rolapitant from OPKO Health, Inc.
TSR-011
TSR-011 is an orally available ALK inhibitor in preclinical development. ALK is known to be involved in certain types of cancers, including subsets of NSCLC, neuroblastoma and lymphoma. For patients in these subsets, the ALK gene is fused to an activating partner or contains point mutations, resulting in constitutive activation of ALK and the growth of cancer cells and tumor development. Inhibition of ALK in these cancer cells results in cell death and tumor growth inhibition or regression. In August 2011, the United States Food and Drug Administration approved the first ALK inhibitor, developed by Pfizer Inc., Xalkori (crizotinib), which was approved for the treatment of patients with locally advanced or metastatic NSCLC that are ALK positive.
The Company competes with GlaxoSmithKline plc, Roche Holding Ltd! . and Sanofi S.A.
Advisors' Opinion:- [By Keith Speights]
Positive response
Clovis wasn't the only company to bring good news about an ovarian cancer drug to ASCO. TESARO� (NASDAQ: TSRO ) announced phase 1 results for�niraparib. Shares of the biotech jumped 16% for the week. - [By Brian Orelli]
Tesaro (NASDAQ: TSRO ) is also up today after announcing that it established a partnership with clinicians to run the phase 3 development of its PARP inhibitor, niraparib. The trial will enroll about 300 breast cancer patients with BRCA mutations, comparing niraparib to investigators' choice of other breast cancer treatments.
- [By Ben Levisohn]
Werber and Eckhard’s favorites include Gilead (GILD) and Celgene (CELG), and they find the “risk/reward…compelling” in Medivation (MDVN) and Tesaro (TSRO).
- [By Jake L'Ecuyer]
Equities Trading UP
Tesaro (NASDAQ: TSRO) shares shot up 20.78 percent to $29.00 after the company reported successful primary and secondary endpoints in final Phase 3 trial for rolapitant.
Top 10 Quality Companies To Watch In Right Now: Universal Display Corporation(PANL)
Universal Display Corporation engages in the research, development, and commercialization of organic light emitting diode (OLED) technologies and materials for use in flat panel display, solid-state lighting, and other product applications. It owns exclusively license or has the sole right to sublicense approximately 1,400 patents issued and pending worldwide. The company licenses and supplies its proprietary UniversalPHOLED phosphorescent OLED technologies and materials to display manufacturers and others. It is also involved in the research, development, and commercialization of other OLED device and manufacturing technologies, including TOLED, which are transparent OLEDs for the fabrication of OLEDs that have transparent cathodes; FOLED that are flexible OLEDs for the fabrication of OLEDs on flexible substrates; OVPD, an organic vapor phase deposition process to deposit the layers of organic material in an OLED; UniversalP2OLED, which are printable phosphorescent OLEDs; OVJP that is an organic vapor jet printing technology; and encapsulation technology for the packaging of flexible OLEDs and other thin-film devices, as well as for use as a barrier film for plastic substrates. In addition, the company provides technology development and support services to third parties for the commercialization of their OLED products. It has strategic relationships with Samsung Mobile Display Co., Ltd.; LG Display Co., Ltd.; AU Optronics Corporation; Sony Corporation; Pioneer Corporation; Panasonic Idemitsu OLED Lighting Co., Ltd.; Tohoku Pioneer Corporation; Moser Baer Technologies, Inc.; Konica Minolta Holdings, Inc.; Denko K.K.; LG Chem, Ltd.; Panasonic Electric Works Co., Ltd.; NEC Lighting, Ltd.; Seiko Epson Corporation; and DuPont Displays, Inc. The company was founded in 1985 and is based in Ewing, New Jersey.
Advisors' Opinion:- [By Seth Jayson]
Universal Display (Nasdaq: PANL ) is expected to report Q1 earnings on May 9. Here's what Wall Street wants to see:
The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Universal Display's revenues will expand 13.7% and EPS will remain in the red.
Top 10 Quality Companies To Watch In Right Now: HMS Holdings Corp (HMSY)
HMS Holdings Corp. provides cost containment, coordination of benefits, and program integrity services. The company?s services enable clients to recover amounts due from liable third parties, reduce fraud, and ensure regulatory compliance. Its coordination of benefits services route claims paid by a government program to the liable third party, which reimburses the government payor; cost avoidance services provide validated insurance coverage information that is used by government payors to reject claims that are the responsibility of a third party; and program integrity services are designed to identify payment errors and recover the erroneous payments. The company also offers audit programs, program design, benefit management, and general and pharmacy systems consulting services. It serves state Medicaid agencies, Medicaid and Medicare managed care plans, government and private self-funded employers, pharmacy benefit managers, child support agencies, the Veterans Health Administration, the Centers for Medicare and Medicaid Services, commercial plans, healthcare payors and sponsors, business outsourcing and technology firms, and government. The company was founded in 1974 and is headquartered in New York, New York.
Advisors' Opinion:- [By Seth Jayson]
HMS Holdings (Nasdaq: HMSY ) is expected to report Q2 earnings on July 26. Here's what Wall Street wants to see:
The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict HMS Holdings's revenues will increase 3.0% and EPS will shrink -8.7%.
No comments:
Post a Comment